CV
CVKD.US Cadrenal Therapeutics, Inc. Common Stock
- Market cap
- USD 5.39M
- P/E
- -
- P/B
- 1.31x
- ROE
- -284.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CVKD.US undervalued?
Graham numberThe Graham number of Cadrenal Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cadrenal Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Cadrenal Therapeutics, Inc. Common Stock yet.
Cadrenal Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial f…
Full company profileCadrenal Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cadrenal Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.27K | -1.98K | -1.88K | - | - |
| Operating Income | -2.70M | -7.63M | -11.0M | -13.5M | -11.7M |
| EBITDA | -6.61M | -8.34M | -10.6M | -13.2M | -11.7M |
| Net Income | -6.71M | -8.36M | -10.7M | -13.2M | -11.6M |
| EPS | -8.66 | -9.63 | -8.73 | -6.64 | -3.99 |
| Balance Sheet | |||||
| Total Assets | 778K | 8.52M | 10.1M | 4.33M | 5.59M |
| Total Liabilities | 6.33M | 827K | 2.68M | 1.59M | 1.50M |
| Shareholders' Equity | -5.55M | 7.69M | 7.44M | 2.74M | 4.09M |
| Cash & Short-term Investments | 32.6K | 8.40M | 10.0M | 4.01M | 2.39M |
| Total Debt | 641K | 21.4K | - | - | - |
| Cash Flow | |||||
| Operating Cash Flow | -1.31M | -3.53M | -7.36M | -12.6M | -10.5M |
| Capital Expenditure | 2.49K | 3.25K | 6.54K | 5.10K | 6.00 |
| Free Cash Flow | -1.32M | -3.53M | -7.36M | -12.6M | -10.5M |
| Ratios | |||||
| ROE | - | -108.6% | -143.2% | -483.3% | -284.4% |
| ROA | -862.8% | -98.1% | -105.2% | -305.9% | -208.2% |
| Debt to Equity | - | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cadrenal Therapeutics, Inc. Common Stock dividends
Cadrenal Therapeutics, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Last stock split: 1:15 on Aug 20, 2024.
Who owns Cadrenal Therapeutics, Inc. Common Stock
- Insiders 9.66%
- Institutions 12.07%
- Public & others 78.28%
- Shares outstanding 3.57M
- Free float 3.22M
Top funds holding CVKD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Abante Quant Value FI | 12.9K | 0.36% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 12.2K | 0.34% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.45K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.04K | 0.06% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 1.11K | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 914.00 | 0.03% | 0.00% | Oct 2026 |
Top institutions holding CVKD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 50.1K | 1.41% | +10.92% | Jun 2026 |
| HRT FINANCIAL LLC | 29.1K | 0.81% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 19.0K | 0.53% | -12.03% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 8.31K | 0.23% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.28K | 0.04% | +226.21% | Jun 2026 |
| UBS Group AG | 1.11K | 0.03% | +36,966.67% | Jun 2026 |
| Coconut Grove Bank | 1.00K | 0.03% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 706.00 | 0.02% | +606.00% | Jun 2026 |
| Hartland & Co | 650.00 | 0.02% | 0.00% | Jun 2026 |
| Quest 10 Wealth Builders, Inc. | 380.00 | 0.01% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 300.00 | 0.01% | 0.00% | Jun 2026 |
| Rockefeller Capital Management L.P. | 150.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 99.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 93.00 | 0.00% | 0.00% | Jun 2026 |
| Integrated Wealth Concepts LLC | 86.00 | 0.00% | 0.00% | Jun 2026 |
| Archer Investment Corporation | 70.00 | 0.00% | +100.00% | Jun 2026 |
| IFP Advisors, LLC | 30.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Cygnus Capital Advisors, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| CURIO WEALTH, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Cadrenal Therapeutics, Inc. Common Stock company profile
- Company name
- Cadrenal Therapeutics, Inc. Common Stock
- Ticker
- CVKD.US
- Exchange
- USA Stocks
- Listed since
- Jan 20, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 822 A1A North, Ponte Vedra, FL, United States, 32082
- Phone
- 904 300 0701
- Website
- cadrenal.com
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc. Common Stock management
3- Mr. Quang X. PhamChairman & CEO · born 1965
- Mr. John P. Sharp CPAInterim CFO & Principal Accounting Officer · born 1965
- Mr. Jeffrey ColeChief Operating Officer · born 1968